| 3.75 Data as of 2:38pm ET |  +0.46 / +13.98%Today’s Change | 0.95 Today|||52-Week Range 5.57 | +251.26% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Medical Specialties | MARKET CAP $21.6M |
Company Description
Response Biomedical Corp. develops, manufactures and markets rapid on-site diagnostic tests for use with its Rapid Analyte Measurement Platform (RAMP) platform for clinical and environmental applications. It develops, manufactures and sells the RAMP system for the medical point of care market including cardiovascular tests and infectious disease tests, and the on-site environmental testing market including biodefense and vector infectious disease testing. RAMP represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use. The RAMP system consists of a reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP clinical tests are commercially available for the early detection of heart attack and congestive heart failure through its commercial partners and distributors. In the non-clinical market, RAMP tests are currently provided for the environmental detection of West Nile Virus and Biodefense applications, including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. The company was founded by William J. Radvak on August 20, 1980 and is headquartered in Vancouver, Canada.
Employees
Shareholders
| Mutual fund holders | -- |
| Individual stakeholders | -- |
| Other institutional | -- |
Top Executives
| Jeffrey L. Purvin, MBA | Chief Executive Officer & Director |
| Bill J. Adams, CFA, MBA | Chief Financial Officer & Secretary |
| Paul C. Harris, PhD | Chief Scientific Officer |
| Patricia Massitti | Vice President-Administration & Communications |
| Barbara Kinnaird-Steen, PhD | Vice President |
.
